T.O. is a trial lawyer who focuses on patent infringement actions with a particular emphasis on representing prominent generic pharmaceutical companies in Hatch-Waxman Act litigation.
T.O. has substantial experience in federal district courts including Delaware, New Jersey, Southern New York, Eastern New York, Northern Illinois, Western Wisconsin, Eastern Texas, Central California, and Northern California.
T.O. has been asked to speak at national conferences regarding Paragraph IV Disputes and has presented on at-risk launches, preliminary injunctions, and the generic perspective on initial stages of a Paragraph IV lawsuit.
T.O. Kong is a trial lawyer in Wilson Sonsini Goodrich & Rosati's litigation department. He focuses on life science patent infringement actions, with a particular emphasis on the representation of prominent pharmaceutical companies in Hatch-Waxman Act and biosimilar litigation.
Shortlisted for "Appellate Litigator of the Year: Intellectual Property" by LMG Life Sciences in July 2022, T.O. has successfully served as lead counsel in disputes regarding the following pharmaceutical products: Injectafer (ferric carboxymaltose), Auryxia (ferric citrate), Pomalyst (pomalidomide), Revlimid (lenalidomide), Jublia (efinaconazole), Kerydin (tavaborole), Suboxone (buprenorphine/naloxone sublingual film), Minivelle (estradiol transdermal patch), Ultiva (remifentanil for injection), Cialis (tadalafil), Adcirca (tadalafil), Gilenya (fingolimod), Brevibloc (esmolol), Lidoderm (lidocaine transdermal patch), Zometa (zoledronic acid infusion), Reclast (zoledronic acid infusion), Daytrana (methylphenidate transdermal patch), Viagra (sildenafil), Velcade (bortezomib), Daliresp (roflumilast), Pradaxa (dabigatran), Doryx (doxycycline), Oracea (doxycycline), Uloric (febuxostat), Banzel (rufinamide), Focalin (dexmethylphenidate), Actoplus Met XR (pioglitazone/metformin), Lescol XL (fluvastatin), Vivelle-Dot (estradiol transdermal patch), and Lunesta (eszopiclone).
T.O. has substantial courtroom experience in federal courts across the country, including Delaware, New Jersey, Southern New York, Eastern New York, Northern Illinois, Western Wisconsin, Eastern Texas, Central California, Northern California and the Federal Circuit.
T.O. Kong is a trial lawyer in Wilson Sonsini Goodrich & Rosati's litigation department. He focuses on life science patent infringement actions, with a particular emphasis on the representation of prominent pharmaceutical companies in Hatch-Waxman Act and biosimilar litigation.
Shortlisted for "Appellate Litigator of the Year: Intellectual Property" by LMG Life Sciences in July 2022, T.O. has successfully served as lead counsel in disputes regarding the following pharmaceutical products: Injectafer (ferric carboxymaltose), Auryxia (ferric citrate), Pomalyst (pomalidomide), Revlimid (lenalidomide), Jublia (efinaconazole), Kerydin (tavaborole), Suboxone (buprenorphine/naloxone sublingual film), Minivelle (estradiol transdermal patch), Ultiva (remifentanil for injection), Cialis (tadalafil), Adcirca (tadalafil), Gilenya (fingolimod), Brevibloc (esmolol), Lidoderm (lidocaine transdermal patch), Zometa (zoledronic acid infusion), Reclast (zoledronic acid infusion), Daytrana (methylphenidate transdermal patch), Viagra (sildenafil), Velcade (bortezomib), Daliresp (roflumilast), Pradaxa (dabigatran), Doryx (doxycycline), Oracea (doxycycline), Uloric (febuxostat), Banzel (rufinamide), Focalin (dexmethylphenidate), Actoplus Met XR (pioglitazone/metformin), Lescol XL (fluvastatin), Vivelle-Dot (estradiol transdermal patch), and Lunesta (eszopiclone).
T.O. has substantial courtroom experience in federal courts across the country, including Delaware, New Jersey, Southern New York, Eastern New York, Northern Illinois, Western Wisconsin, Eastern Texas, Central California, Northern California and the Federal Circuit.